NanoViricides, Inc. (NNVC)
-OTC BB 0.64 
0.02(3.23%) 3:34PM EDT
| Prev Close: | 0.62 |
|---|
| Open: | 0.63 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 0.75 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.58 - 0.67 |
|---|
| 52wk Range: | 0.32 - 0.80 |
|---|
| Volume: | 368,706 |
|---|
| Avg Vol (3m): | 265,306 |
|---|
| Market Cap: | 105.31M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.06 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- NANOVIRICIDES, INC. FinancialsEDGAR Online Financials(Tue 1:04PM EDT)
- NANOVIRICIDES, INC. Files SEC form 10-Q/A, Quarterly ReportEDGAR Online(Mon, May 20)
- NANOVIRICIDES, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- NanoViricides, Inc. Brings in Experienced Executive as Interim CFOBusiness Wire(Mon, May 13)
- NanoViricides to Present at the 2013 BIO International Convention in Chicago TodayBusiness Wire(Wed, Apr 24)
- NanoViricides Anticipates FluCide™ Drug Candidates to be Effective Against H7N9Business Wire(Mon, Apr 22)
- NanoViricides President Dr. Diwan Invited to Present a Seminar at the Center for Biological Physics and the California NanoSystems Institute at UCLABusiness Wire(Wed, Mar 20)
- NanoViricides to Lead Sessions at the Symposium on Nanomedicines- Roadmap to Commercialization, in Rockville, MD tomorrowBusiness Wire(Tue, Mar 5)
- NANOVIRICIDES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material DefinitEDGAR Online(Thu, Feb 28)
- NanoViricides Announces Retirement of Its Series C Convertible Preferred Stock Held by Seaside 88, LP - Company Reports Having More Than Two Years of Cash on HandBusiness Wire(Wed, Feb 27)
- NanoViricides, Inc. Announces that Renovation for its cGMP Clinical Drug Facility has Begun; also Addresses Shareholder Concern - Knows No Reason for the Price Drop YesterdayBusiness Wire(Tue, Feb 26)
- NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Phase I Clinical Trials of its First Drug CandidateBusiness Wire(Tue, Feb 19)
- NANOVIRICIDES, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, Feb 14)
- NanoViricides to Present at the 15th Annual BIO-CEO Conference in NYC TomorrowBusiness Wire(Mon, Feb 11)
- NanoViricides Raises $6M from Equity Investors - Reports Having Sufficient Funds for the Initial Human Clinical Trials of its Broad-spectrum anti-Influenza DrugBusiness Wire(Mon, Feb 4)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
NanoViricides, Inc., a nano-biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of viral infections.
View More